Mind Medicine, Inc.

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

Actuate Therapeutics, Inc. grossed $22.4m from its initial public offering of 2.8 million shares priced at $8 each in the 15th biopharmaceutical company IPO in the US in 2024. It was not the smallest

Lykos Therapeutics is not taking the rejection of midomafetamine lying down. The company said late on 9 August that the product, a version of the illicit drug MDMA for the treatment of post-traumatic

Mind Medicine, Inc. (MindMed) plans to take MM120 (lysergide D-tartrate), a proprietary low-dose formulation of the psychedelic drug LSD, into Phase III clinical trials in generalized anxiety disorde